Trial Information

Treatment of Mature B-cell Lymphoma/Leukaemia A SFOP LMB 96/CCG 5961/UKCCSG NHL 9600 Cooperative Study

Group B: Randomized trial with factorial design. The 4 treatment arms are standard LMB89
therapy B, reduction of cyclophosphamide (CPM) in COPADM2, deletion of COPADM3, both
reduction and deletion. Randomization occurs following COPADM1 and is stratified for
national group, histology (large cell; small non cleaved cell) and stage (Murphy I orII;
Murphy III+LDH<2N; Murphy III+LDH>2N or Murphy IV).

The primary analysis questions are whether reducing CPM dose in COPADM2 results in a smaller
long-term EFS whether omitting COPADM3 results in a smaller long-term EFS

Group C: Randomized trial. The 2 treatment arms are standard LMB89 therapy C versus
reduction of CYVE + deletion of the last 3 maintenance courses. Randomization occurs
following COPADM2 and is stratified for national group, histology (large cell; small non
cleaved cell) and CNS disease.

The primary analysis question is whether reducing CYVE and omitting the last 3 maintenance
courses result in a smaller long-term EFS than standard LMB 89 treatment C